← TrialMatch
HomeTrials

Endoscopic Mucosal Injection Versus Ultrasound-Guided Injection of Triamcinolone to Treat

This study employs a multicenter, randomized controlled trial method, where patients meeting the inclusion criteria for subglottic stenosis are randomly divided into two groups. These groups are respectively undergoing translaryngeal endoscopic mucosal injection and ultrasound-guided injection of triamcinolone treatmen

Condition(s)Subglottic Stenosis
StatusRecruiting
PhaseNA
Study typeInterventional
SummaryThis study employs a multicenter, randomized controlled trial method, where patients meeting the inclusion criteria for subglottic stenosis are randomly divided into two groups. These groups are respectively undergoing translaryngeal endoscopic mucosal injection and ultrasound-guided injection of triamcinolone treatment. The comparison will focus on various indicators such as therapeutic effect, incidence of adverse reactions, treatment costs, and hospital resource utilization between the two groups. The safety and effectiveness will be compared to determine the relative merits of the two treatment methods.
Who can participateInclusion Criteria: * 1: "Diagnosed with subglottic stenosis through laryngoscopic examination or imaging studies such as CT." * 2: "Experiencing symptoms related to subglottic stenosis, such as breathing difficulties, hoarseness, etc." Exclusion Criteria: * 1: "Severe cardiopulmonary dysfunction, patients extremely debilitated and unable to tolerate the procedure." * 2: "Patients allergic to lidocaine, midazolam, triamcinolone, or any of their components." * 3: "Pregnant or lactating women." * 4: "Unstable angina, congestive heart failure, severe bronchial asthma." * 5: "Severe hypertension and arrhythmias, hemodynamically unstable, and severe respiratory failure (PaO2 \<60mmHg after oxygen therapy or mechanical ventilation)." * 6: "Known coagulation dysfunction, inability to stop anticoa
Ages18 Years to 65 Years
SexAll
Lead sponsorChina-Japan Friendship Hospital
LocationsBeijing, Beijing Municipality, China
Start date2024-03-10
NCT IDNCT06275269
Official listinghttps://clinicaltrials.gov/study/NCT06275269

🔍 Search all trials →